Teva Pharmaceutical Industries Basic Shares Outstanding 2010-2025 | TEVA
Teva Pharmaceutical Industries annual/quarterly basic shares outstanding history and growth rate from 2010 to 2025. Basic shares outstanding can be defined as the number of shares held by shareholders including insiders but not including a company's treasury shares.
- Teva Pharmaceutical Industries basic shares outstanding for the quarter ending March 31, 2025 were $1.138B, a 1.34% increase year-over-year.
- Teva Pharmaceutical Industries basic shares outstanding for the twelve months ending March 31, 2025 were $4.535B, a 1.16% increase year-over-year.
- Teva Pharmaceutical Industries annual basic shares outstanding for 2024 were $1.131B, a 1.07% increase from 2023.
- Teva Pharmaceutical Industries annual basic shares outstanding for 2023 were $1.119B, a 0.81% increase from 2022.
- Teva Pharmaceutical Industries annual basic shares outstanding for 2022 were $1.11B, a 0.73% increase from 2021.
Teva Pharmaceutical Industries Annual Basic Shares Outstanding
(Millions of US $) |
| 2024 |
$1,131 |
| 2023 |
$1,119 |
| 2022 |
$1,110 |
| 2021 |
$1,102 |
| 2020 |
$1,095 |
| 2019 |
$1,091 |
| 2018 |
$1,021 |
| 2017 |
$1,016 |
| 2016 |
$955 |
| 2015 |
$855 |
| 2014 |
$853 |
| 2013 |
$849 |
| 2012 |
$872 |
| 2011 |
$890 |
| 2010 |
$896 |
| 2009 |
$872 |
Teva Pharmaceutical Industries Quarterly Basic Shares Outstanding
(Millions of US $) |
| 2025-03-31 |
$1,138 |
| 2024-12-31 |
$1,131 |
| 2024-09-30 |
$1,133 |
| 2024-06-30 |
$1,133 |
| 2024-03-31 |
$1,123 |
| 2023-12-31 |
$1,119 |
| 2023-09-30 |
$1,121 |
| 2023-06-30 |
$1,120 |
| 2023-03-31 |
$1,115 |
| 2022-12-31 |
$1,110 |
| 2022-09-30 |
$1,111 |
| 2022-06-30 |
$1,110 |
| 2022-03-31 |
$1,107 |
| 2021-12-31 |
$1,102 |
| 2021-09-30 |
$1,103 |
| 2021-06-30 |
$1,103 |
| 2021-03-31 |
$1,099 |
| 2020-12-31 |
$1,095 |
| 2020-09-30 |
$1,096 |
| 2020-06-30 |
$1,096 |
| 2020-03-31 |
$1,093 |
| 2019-12-31 |
$1,091 |
| 2019-09-30 |
$1,092 |
| 2019-06-30 |
$1,092 |
| 2019-03-31 |
$1,090 |
| 2018-12-31 |
$1,021 |
| 2018-09-30 |
$1,018 |
| 2018-06-30 |
$1,018 |
| 2018-03-31 |
$1,017 |
| 2017-12-31 |
$1,016 |
| 2017-09-30 |
$1,017 |
| 2017-06-30 |
$1,017 |
| 2017-03-31 |
$1,016 |
| 2016-12-31 |
$955 |
| 2016-09-30 |
$979 |
| 2016-06-30 |
$914 |
| 2016-03-31 |
$913 |
| 2015-12-31 |
$855 |
| 2015-09-30 |
$851 |
| 2015-06-30 |
$849 |
| 2015-03-31 |
$851 |
| 2014-12-31 |
$853 |
| 2014-09-30 |
$855 |
| 2014-06-30 |
$852 |
| 2014-03-31 |
$850 |
| 2013-12-31 |
$849 |
| 2013-09-30 |
$845 |
| 2013-06-30 |
$849 |
| 2013-03-31 |
$855 |
| 2012-12-31 |
$872 |
| 2012-09-30 |
$869 |
| 2012-06-30 |
$871 |
| 2012-03-31 |
$880 |
| 2011-12-31 |
$890 |
| 2011-09-30 |
$888 |
| 2011-06-30 |
$892 |
| 2011-03-31 |
$897 |
| 2010-12-31 |
$899 |
| 2010-09-30 |
$899 |
| 2010-06-30 |
$895 |
| 2010-03-31 |
$892 |
| 2009-12-31 |
$888 |
| 2009-09-30 |
$884 |
| 2009-06-30 |
$860 |
| 2009-03-31 |
$857 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$19.026B |
$16.544B |
|
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
|
